Holen Sie sich die Stockscreener-App
370.00
1.24%
4.54
Handel nachbörslich:
370.00
Schlusskurs vom Vortag:
$365.46
Offen:
$365.5
24-Stunden-Volumen:
1.88M
Relative Volume:
1.40
Marktkapitalisierung:
$48.88B
Einnahmen:
$3.21B
Nettoeinkommen (Verlust:
$43.57M
KGV:
1,538.46
EPS:
0.2405
Netto-Cashflow:
$221.36M
1W Leistung:
+2.99%
1M Leistung:
-9.25%
6M Leistung:
+13.75%
1J Leistung:
+38.82%
1-Tages-Spanne:
$363.36
$376.87
1-Wochen-Bereich:
$347.76
$376.87
52-Wochen-Spanne:
$205.87
$495.55
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
Firmenname
Alnylam Pharmaceuticals Inc
Sektor
Branche
Telefon
(617) 551-8200
Adresse
675 WEST KENDALL STREET, CAMBRIDGE, MA
Vergleichen Sie ALNY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
370.00 | 48.28B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
VRTX
Vertex Pharmaceuticals Inc
|
467.35 | 117.00B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.51 | 78.75B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
827.02 | 50.52B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
338.81 | 37.81B | 4.98B | 69.59M | 525.67M | 0.5197 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-07 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-08-04 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-08-04 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2025-07-30 | Fortgesetzt | Raymond James | Outperform |
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-03-31 | Eingeleitet | Redburn Atlantic | Buy |
| 2025-03-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-11-12 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-08-16 | Hochstufung | Goldman | Neutral → Buy |
| 2024-02-16 | Herabstufung | Goldman | Buy → Neutral |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-10-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-09-29 | Eingeleitet | Raymond James | Outperform |
| 2023-05-05 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-26 | Eingeleitet | SMBC Nikko | Neutral |
| 2023-03-21 | Eingeleitet | Bernstein | Outperform |
| 2023-01-18 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-09-09 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-06-27 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-06-07 | Eingeleitet | William Blair | Outperform |
| 2022-04-25 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-01 | Eingeleitet | Citigroup | Buy |
| 2022-02-03 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-01-03 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-11-22 | Hochstufung | Goldman | Neutral → Buy |
| 2021-11-22 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-01 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-10-04 | Hochstufung | UBS | Neutral → Buy |
| 2021-08-04 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-02-22 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-02-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-02-12 | Bestätigt | H.C. Wainwright | Buy |
| 2021-01-25 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-30 | Fortgesetzt | Berenberg | Hold |
| 2020-09-08 | Eingeleitet | Citigroup | Buy |
| 2020-08-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2020-05-07 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-04-24 | Fortgesetzt | Evercore ISI | Outperform |
| 2020-03-19 | Eingeleitet | Berenberg | Buy |
| 2019-12-19 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-11-20 | Eingeleitet | Oppenheimer | Outperform |
| 2019-11-13 | Eingeleitet | BofA/Merrill | Buy |
| 2019-05-23 | Fortgesetzt | Goldman | Neutral |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-03-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-03-05 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-01-23 | Eingeleitet | UBS | Neutral |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-08-13 | Bestätigt | Stifel | Buy |
| 2018-08-07 | Hochstufung | Stifel | Hold → Buy |
| 2018-05-04 | Bestätigt | Stifel | Hold |
| 2018-03-28 | Eingeleitet | Evercore ISI | In-line |
Alle ansehen
Alnylam Pharmaceuticals Inc Aktie (ALNY) Neueste Nachrichten
Should Alnylam’s Aggressive 2026 Revenue Guidance Reframe the Risk‑Reward for Alnylam Pharmaceuticals (ALNY) Investors? - simplywall.st
31,152 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Bought by Rakuten Investment Management Inc. - MarketBeat
Nanomedicine Market Reached USD 169.51 Billion in 2024, to Reach - openPR.com
Amyloidosis Therapeutic Market to Worth Over US$ 6.37 Billion by 2033 | Astute Analytica - GlobeNewswire Inc.
Technical Reactions to ALNY Trends in Macro Strategies - Stock Traders Daily
RBC Capital Maintains Rating but Lowers Alnylam Pharmaceuticals (ALNY) Price Target | ALNY Stock News - GuruFocus
Alnylam Pharmaceuticals (NASDAQ:ALNY) Given New $376.00 Price Target at Wells Fargo & Company - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Lowered to $465.00 at Royal Bank Of Canada - MarketBeat
356,529 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Purchased by Massachusetts Financial Services Co. MA - MarketBeat
Allstate Corp Acquires Shares of 4,571 Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Price Action: What analysts say about Alnylam Pharmaceuticals Inc stockWeekly Investment Summary & High Accuracy Investment Entry Signals - baoquankhu1.vn
Alnylam Wins EC Nod for Label Expansion of Amvuttra for ATTR-CM - MSN
4 Next-Gen Candidates That Could Form the Future of Alzheimer’s Treatment - BioSpace
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Sees Significant Growth in Short Interest - MarketBeat
Aug Volume: How does Alnylam Pharmaceuticals Inc perform in inflationary periodsJuly 2025 Opening Moves & Stock Portfolio Risk Management - baoquankhu1.vn
Is It Time To Reassess Alnylam Pharmaceuticals (ALNY) After Recent RNAi Pipeline Progress? - simplywall.st
Wolverine Asset Management LLC Makes New Investment in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Campbell & CO Investment Adviser LLC Makes New Investment in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
A Look Into Alnylam Pharmaceuticals Inc's Price Over Earnings - Sahm
Insider Selling: Jeffrey V Poulton Unloads $1.01M Of Alnylam Pharmaceuticals Stock - Benzinga
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
How Does Geopolitics Affect the Life Sciences Industry? 3 Executives Weigh In - MedCity News
Alnylam EVP Pushkal Garg sells $547k in stock By Investing.com - Investing.com South Africa
Alnylam EVP Pushkal Garg sells $547k in stock - Investing.com
Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Sells $1,008,778.60 in Stock - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Sells $547,933.70 in Stock - MarketBeat
Insider Selling: Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Sells 1,510 Shares of Stock - MarketBeat
Insider Selling: Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Sells 2,290 Shares of Stock - MarketBeat
JPM preannouncements: Why Alnylam and Sarepta lost, but Day One won - MSN
Is It Time To Reassess Alnylam (ALNY) After Recent Share Price Pullback? - Yahoo Finance
JPM26: 2025 a “breakout year” for rare disease biotechs - Yahoo Finance
Aug Gainers: What is ORLYs book value per shareQuarterly Profit Summary & Technical Entry and Exit Alerts - baoquankhu1.vn
A Look At Alnylam Pharmaceuticals (ALNY) Valuation After Unveiling Its Alnylam 2030 Growth Plan - Yahoo Finance
Alnylam Pharmaceuticals (ALNY) Is Down 9.0% After Ambitious 2026 Guidance And 2030 Plan Reveal - Yahoo Finance
Market Review: What dividend safety score for Alnylam Pharmaceuticals Inc stockIndex Update & Reliable Intraday Trade Alerts - moha.gov.vn
H.C. Wainwright reiterates Buy rating on Alnylam stock with $570 price target - Investing.com UK
Tokio Marine Asset Management Co. Ltd. Takes $2.03 Million Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Sumitomo Mitsui Trust Group Inc. Grows Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals CEO on Development Goals, Profitability - marketscreener.com
Alnylam stock sinks nearly 7% after Amvuttra revenue miss; what to watch next for ALNY - TechStock²
JPM preannouncements take their toll as Alnylam slides, Tempus, Day One pop - MSN
Lobbying Update: $70,000 of ALNYLAM PHARMACEUTICALS INC. lobbying was just disclosed - Quiver Quantitative
JPM 2026: Year kicks off with biopharma Q4 revenue and guidance - BioWorld MedTech
Alnylam stock slides after “Alnylam 2030” plan, Amvuttra Q4 sales come up short - TechStock²
Alnylam Pharmaceuticals (NASDAQ:ALNY) Shares Gap Down After Analyst Downgrade - MarketBeat
Alnylam Pharmaceuticals Unveils “Alnylam 2030” as Amvuttra Drives Breakout Growth at JPMorgan Conf. - MarketBeat
JPM Kicks Off With Alnylam In the Red; But Others Surge - Investor's Business Daily
What's Going On With Alnylam Pharma Stock Monday?Alnylam Pharmaceuticals (NASDAQ:ALNY) - Benzinga
Alnylam (ALNY) Projects Strong Revenue Growth for 2026 Amidst TT - GuruFocus
AbbVie buys into PD-1/VEGF sweepstakes; Alnylam and Vertex set expectations - BioPharma Dive
Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Cut to $529.00 by Analysts at Bank of America - MarketBeat
Finanzdaten der Alnylam Pharmaceuticals Inc-Aktie (ALNY)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.30%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):